Home > Insider Trading > Filing (0001209191-22-002472)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178879	Amicus Therapeutics Inc.	FOLD	Pharmaceutical Preparations (2834)	200422823

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1400973	F John Crowley	C/O Amicus Therapeutics, Inc. 3675 Market Street Philadelphia PA 19104	Chairman & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-01-05	63,543	$12.18	655,131	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	64,895	Indirect	By Trust

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Comprised of 46,910 shares received from the 2019 PRSU grant, awarded for exceeding the Galafold revenue goal for the applicable measurement period, and 16,333 shares received from the 2018 annual grant, the receipt of which were deferred by Mr. Crowley until January 1, 2022.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.95 to $12.59 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.